Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy - ACR Meeting Abstracts

Abstract Number: 2485

Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy

Angela Gupta¹, Sofi Damjanovska ², David Zidar ³, Donald Anthony ⁴ and Maya Mattar ³, ¹Case Western Reserve University, Cleveland, ²Case Western Reserve University, Cleveland Heights, OH, ³Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ascvd score and bsdmard therapy, psoriasis, Psoriatic arthritis, rdw

Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there is variation in red cell size (anisocytosis). RDW has been found to be a predictor of cardiovascular disease (CVD), but is not commonly incorporated in current risk evaluation instruments. Research has linked an elevated RDW to disease activity in psoriasis, but limited data is available on the relationship between these parameters and psoriatic arthritis.

Methods: We performed a retrospective chart review study examining the relationship between RDW, MPV, hemoglobin, absolute lymphocyte count (ALC), and atherosclerotic cardiovascular disease (ASCVD) 10 year risk score (incorporating age, hypertension status, diabetes mellitus (DM) status, lipid profile, and smoking status) in a cohort of patients with psoriatic arthritis, taking into account their HLA-B27 status, race, and treatment history.

Results: RDW was positively correlated with ASCVD score, and RDW was found to decrease over 12 months for all patients started on bDMARD therapy. As expected, we found positive correlations between ASCVD score, hemoglobin A1c, and age, and negative correlations between ASCVD score, hemoglobin, and albumin. Patients started on NSAID therapy had a statistically significant increase in RDW between time 0 and 6 months (p = 0.03), but this was not maintained at twelve months. Patients on csDMARD therapy did not experience a statistically significant change in RDW at 6 or 12 months, while patients on bDMARD and bDMARD + csDMARD therapy experienced a statistically significant decline in RDW from 0 to 6 months (p = 0.046) and from 0 to 12 months (p = 0.040). When patients on bDMARD therapy were analyzed alone, a trend towards a decline in RDW from 0 to 12 months was also observed (p = 0.11).

Conclusion: This data shows that not only is there is a positive correlation between RDW and traditional cardiovascular risk factors, as represented by ASCVD score, in patients with psoriatic arthritis, but also that bDMARD therapy appears to be associated with decreasing RDW in these patients over time, the latter consistent with RDW in part reflecting disease activity. Whether RDW adds to cardiovascular risk assessment beyond traditional cardiovascular risk factor analysis is yet to be determined. Data here suggest it may be a viable candidate since it appears to reflect both disease activity and traditional risk factors. More investigation related to bDMARD therapy and other non-conventional parameters of disease activity in psoriatic arthritis as they relate to CVD is warranted. This could have powerful clinical implications, as having other approaches of monitoring disease activity (aside from ESR and CRP) would be beneficial for patients.

Figure 1 depicts the positive linear correlation between ASCVD score and RDW -r =.35, p-value = 0.001-.

Figure 2 depicts the relationship between RDW over time for patients on bDMARD therapy alone. A trend towards a decline in RDW from 0 to 12 months was observed -p = 0.11-.

Figure 3 shows the relationship between RDW over time for patients on both bDMARD therapy and bDMARD and cDMARD therapy. A statistically significant decline in RDW from 0 to 6 months -p = 0.046- and from 0 to 12 months -p = 0.040- was observed.

Disclosure: A. Gupta, None; S. Damjanovska, None; D. Zidar, None; D. Anthony, None; M. Mattar, None.

To cite this abstract in AMA style:

Gupta A, Damjanovska S, Zidar D, Anthony D, Mattar M. Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/red-cell-distribution-width-positively-correlates-with-atherosclerotic-cardiovascular-disease-risk-score-in-psoriatic-arthritis-and-decreases-with-bdmard-therapy/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/red-cell-distribution-width-positively-correlates-with-atherosclerotic-cardiovascular-disease-risk-score-in-psoriatic-arthritis-and-decreases-with-bdmard-therapy/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].